The notices it replaced
Its page names no earlier notice: it is new, or it does not say.
Replaced by RFA-NS-23-012.
Who won it before
1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $18,136,504 in first-year total cost, median $18,136,504.
Most frequent study sections
- Special Emphasis Panel[ZNS1 SRB-E (05)]1
Most frequent institutions
- MASSACHUSETTS GENERAL HOSPITAL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral Sclerosis1UF1NS131791-01 | BABU, SUMABERRY, JAMES DALEPAGANONI, SABRINA | MASSACHUSETTS GENERAL HOSPITAL, MA | $18,136,504 | ZNS1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-11-0.1.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.